Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 296

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.

Rivastigmine for Alzheimer's disease

Birks, Jacqueline, Grimley Evans, John, Iakovidou, Vasso, Tsolaki, Magda · 2009 · Cochrane Database of Systematic Reviews

Abstract

BACKGROUND: Alzheimer's disease (AD) is the commonest cause of dementia affecting older people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in relevant parts of the brain by the use of cholinesterase inhibitors to delay the breakdown of acetylcholine released into synaptic clefts. Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose, was associated with significant adverse effects including hepatotoxicity. Other cholinesterase inhibitors, including rivastigmine, with superior properties in terms of specificity of action and low risk of adverse effects, have now been introduced. Rivastigmine has received approval for use in 60 countries including all member states of the European Union and the USA. OBJECTIVES: To determine the clinical efficacy and safety of rivastigmine for patients with dementia of Alzheimer's type. SEARCH STRATEGY: The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (CDCIG), The Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS were searched on 27 March 2008 using the terms: Rivastigmine OR exelon OR ENA OR "SDZ ENA 713" . The CDCIG Specialized Register contains records from all major health care databases (The Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS) as well as from many clinical trials registries and grey literature sources. SELECTION CRITERIA: All unconfounded, double-blind, randomized trials in which treatment with rivastigmine was administered to patients with dementia of the Alzheimer's type for more than two weeks and its effects compared with those of placebo in a parallel group of patients. DATA COLLECTION AND ANALYSIS: One reviewer (JSB) applied study selection criteria, assessed the quality of studies and extracted data. MAIN RESULTS: Nine trials, involving 4775 participants, were included in the analyses. Use of rivastigmine in high doses was associated with statistically significant benefits on several measures. High-dose rivastigmine (6 to 12 mg daily) was associated with a two-point improvement in cognitive function on the ADAS-Cog score compared with placebo (weighted mean difference -1.99, 95% confidence interval -2.49 to -1.50, on an intention-to-treat basis) and a 2.2 point improvement in activities of daily living assessed on the Progressive Deterioration Scale (weighted mean difference -2.15, 95% confidence interval -3.16 to -1.13, on an intention-to-treat basis) at 26 weeks. At lower doses (4 mg daily or lower) differences were in the same direction but were statistically significant only for cognitive function. There were statistically significantly higher numbers of events of nausea, vomiting, diarrhoea, anorexia, headache, syncope, abdominal pain and dizziness among patients taking high-dose rivastigmine than among those taking placebo. There was some evidence that adverse events might be less common with more frequent, smaller doses of rivastigmine. The 2008 update includes a new study testing two types of rivastigmine transdermal patch, one delivering a higher dose than previously tested (17.4 mg/day) and a smaller patch delivering 9.6 mg/day. The efficacy of the smaller patch was not significantly different compared with the capsules of similar daily dose, but was associated with significantly fewer adverse events of nausea, vomiting, dizziness and asthenia. The efficacy of the larger patch was not significantly different compared with the smaller patch, but the smaller patch was associated with significantly fewer adverse events of nausea, vomiting, weight loss and dizziness. There appears to be advantages associated with the smaller patch compared with both the higher dose patch and the 6-12 mg/day capsules. AUTHORS' CONCLUSIONS: Rivastigmine appears to be beneficial for people with mild to moderate Alzheimer's disease. In comparisons with placebo, improvements were seen in the rate of decline of cognitive function, activities of daily living, and severity of dementia with daily doses of 6 to 12 mg. Adverse events were consistent with the cholinergic actions of the drug. A transdermal patch has been tested in one trial, and there is evidence that the lower dose smaller patch is associated with fewer side effects than the capsules or the higher dose larger patch and has comparable efficacy to both. This review has not examined economic data.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd001191.pub2

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 38

  1. Anand, 1996, Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's Disease: an overview, J Drug Dev Clin Pract, 8, 109
  2. Anand, 1996, Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's Disease: an overview, J Drug Dev Clin Pract, 8, 109
  3. Anand, 1996, Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: an overview, J Drug Dev Clin Pract, 8, 109
  4. Cutler, 1995, Safety and tolerance of ENA 713 in patients with alzheimer's disease, Biological Psychiatry, 37, 643
  5. Anand, 2001, Effects of Alzheimer's disease severity on activities of daily living with long-term rivastigmine treatment, Journal of the American Geriatrics Society, 49, S151
  6. Hebert, 1999, [Alzheimer disease: efficacy and tolerance of rivastigmine], Presse Medicale, 28, 1757
  7. Rösler M Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [Erratum] British Medical Journal 2001 1456
  8. Rösler, 1997, A double-blind placebo controlled study of ENA 713 in Alzheimer's disease (DAT), Pharmacopsychiatry, 30, 212
  9. Rösler, 1998, Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease, Behavioural-Neurology, 11, 211, 10.1155/1999/168023 · DOI
  10. Burns, 2004, Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease, International Journal of Geriatric Psychiatry, 19, 243, 10.1002/gps.1058 · DOI
  11. Farlow, 2003, Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial, Archives of Neurology, 60, 843, 10.1001/archneur.60.6.843 · DOI
  12. Burns, 2004, Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease, International Journal of Geriatric Psychiatry, 19, 243, 10.1002/gps.1058 · DOI
  13. Doraiswamy, 2000, Cognitive effects of rivastigmine in patients with mild to moderate alzheimer's disease compared to those with moderately-severe to severe AD, Clinical Neuropschological Assessment, 1, 12
  14. Doraiswamy, 2000, Long term cognitive effects in Alzheimer's disease patients stratified by vascular risk score and treated for 1 year with rivastigmine, Clinical Neuropschological Assessment, 1, 14
  15. Farlow, 2003, Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial, Archives of Neurology, 60, 843, 10.1001/archneur.60.6.843 · DOI
  16. Farlow, 2001, Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression, Archives of Neurology, 58, 417, 10.1001/archneur.58.3.417 · DOI
  17. Krishnan, 1999, Rivastigmine slows stage specific global deterioration in Alzheimer's disease, Journal of the American Geriatrics Society, 47, S3
  18. Tai, 2000, The safety and efficacy of Exelon in Alzheimer's patients: A multicentre, randomized, 26-week study in Taiwan, International Journal of Neuropsychopharmacology, 3, S356
  19. Cummings, 2000, Abstract S79.002, Neurology, 54, A468
  20. Anon Double-blind trial will compare two anti-alzheimer's drugs Journal of Dementia Care 6
  21. Bullock, 2005, Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period, Current Medical Research and Opinion, 21, 1317, 10.1185/030079905X56565 · DOI · Paper page
  22. Bullock, 2002, Rationale and design of EXCEED, a 24-month, double-blind study comparing rivastigmine and donepezil, Annals of Neurology, 52, 30
  23. Malsch, 2001, [Treatment of Alzheimer's disease: Tolerability of rivastigmine during the initial period], Psycho, 27, 337
  24. Wang, 2001, The treatment by using rivastigmine for patients with alzheimer disease: results of a multicenter, randomized, open-labeled, controlled clinical trial, Chinese Journal of Neurology, 34, 210
  25. Wang, 2003, [Efficacy of rivastigmine in treating mild to severe alzheimer's disease with different hachinski ischemia index], Chinese Journal of Neurology, 36, 44
  26. Bullock, 2001, The tolerability, ease of use and efficacy of donepezil and rivastigmine in Alzheimer's disease patients: a 12-week, multinational, comparative study, Journal of the American Geriatrics Society, 49, S19
  27. Benton, 1974, Revised visual retention test
  28. Brunner, 1990, Eine Validierungsstudie mit der NOSGER (Nurses' Observation Scale for Geriatric Patients), einem neuen Beurteilungsinstrument für die Psychogeriatrie, Zeitschr für Psychologie, XIX, 211
  29. Burns, 2004, Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease, International Journal of Geriatric Psychiatry, 19, 243, 10.1002/gps.1058 · DOI
  30. Cohen-Mansfield, 1995, Assessment of disruptive behaviour/agitation in the elderly: function, methods and difficulties, Journal of Geriatric Psychiatry Neurology, 8, 52
  31. 1994, Diagnostic and Statistical Manual of Mental Disorders
  32. Farlow, Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial, Archives of neurology, 60, 843, 10.1001/archneur.60.6.843 · DOI
  33. Grossberg, 2004, Erratum, American Journal of Geriatric Psychiatry, 12, 679, 10.1097/00019442-200411000-00016 · doi:10.1097/00019442-200411000-00016
  34. Guy, 1976, .,, 1976
  35. Kaufer, 2004, Consistent Long-term Efficacy of Rivastigmine in Mild, Moderate and Moderately Severe Alzheimer's Disease, NeuroBiology of Aging, 25, 101, 10.1016/S0197-4580(04)80340-3 · doi:10.1016/s0197-4580(04)80340-3
  36. Reisberg, 1994, CIBIC-plus interview guide
  37. Schneider, 1998, Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease, International Journal of Geriatric Psychopharmacology, 1, S26
  38. Wechsler, 1987, Wechsler Memory Scale-Revised (WMS-R)

Cited by

See all 296

Metadata

Authors
Birks, J., Grimley Evans, J., Iakovidou, V., & Tsolaki, M.
Venue
Cochrane Database of Systematic Reviews
Published
2009-04-15
Issue
2
Pages
CD001191-CD001191
ISSN
1361-6137 (ISSN-L)
OpenAlex
W4211075001
Cited by
296
References
82
Type
reference entry
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.